Open Access

Serum soluble interleukin‑2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions

  • Authors:
    • Jun Murakami
    • Kotaro Arita
    • Akinori Wada
    • Hiroshi Mihara
    • Hideki Origasa
    • Mika Kigawa
    • Ichiro Yasuda
    • Tsutomu Sato
  • View Affiliations

  • Published online on: September 11, 2019     https://doi.org/10.3892/mco.2019.1922
  • Pages: 474-482
  • Copyright : © Murakami et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The serum soluble interleukin 2 receptor (sIL2R) level is elevated in patients with most types of lymphoid neoplasms, and is also elevated in patients with solid tumors or reactive conditions, such as severe inflammation. To evaluate the diagnostic significance of sIL2R levels for the screening and differential diagnosis of lymphomas, data from 248 consecutive adult patients with suspected lymphoma were retrospectively analyzed in order to determine its diagnostic characteristics and the clinical parameters that affect diagnosis. In 133 patients with aggressive or indolent lymphomas or related neoplasms, the sIL2R level was higher (median: 920 U/ml, standard deviation: 7,312 U/ml) compared with that of 115 patients with other diagnoses (median: 520 U/ml, standard deviation: 727 U/ml), including solid tumors, infection, inflammation, and others. When the cutoff value of sIL2R was 1,104 U/ml, the specificity was 80%, at which point lymphoma was suspected. When the threshold levels were increased from 1,500 to 2,000 U/ml, the specificity increased from 87 to 93%, with the positive likelihood ratio increasing from 2.99 to 4.97, strongly suggesting the diagnosis of lymphoma. The receiver operating characteristic curve for prediction of lymphoma by sIL2R revealed that the area under the curve was 0.695. The curve was nearest to the left corner of the plot when the threshold was 1,946 U/ml; at this point, the sensitivity, specificity and positive likelihood ratio were 35%, 93% and 5.06, respectively. Multivariate analysis demonstrated that an age >46 years and lactate dehydrogenase level >173 U/l appeared to increase the risk of malignant lymphoma diagnosis. Although sIL2R appears to be a less specific marker for the screening of lymphomas, its detection at higher levels strongly suggests the diagnosis of lymphomas. Therefore, sIL2R may be more useful compared with any other parameter for lymphoma diagnosis, provided other false‑positive conditions are taken into consideration.

References

1 

Yasuda N, Takamatsu T, Kanoh T and Uchino H: Serum levels of soluble interleukin 2 receptor in patients with non-haematological disorders. Br J Haematol. 69:5731988. View Article : Google Scholar : PubMed/NCBI

2 

Rubin LA, Galli F, Greene WC, Nelson DL and Jay G: The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine. 2:330–336. 1990. View Article : Google Scholar : PubMed/NCBI

3 

Bien E and Balcerska A: Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: A review. Biomarkers. 13:1–26. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Yasuda N, Lai PK, Ip SH, Kung PC, Hinuma Y, Matsuoka M, Hattori T, Takatsuki K and Purtilo DT: Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood. 71:1021–1026. 1988.PubMed/NCBI

5 

Ambrosetti A, Nadali G, Vinante F, Ricetti MM, Todeschini G, Morosato L, de Sabata D, Bergamo Andreis IA, Chilosi M, Semenzato G, et al: Soluble interleukin-2 receptor in hairy-cell leukemia: A reliable marker of disease. Int J Clin Lab Res. 23:34–37. 1993. View Article : Google Scholar : PubMed/NCBI

6 

Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, Masunari T, Fujiwara M, Nishisaka T, Sasaki N, Sadahira Y, et al: Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One. 8:e787302013. View Article : Google Scholar : PubMed/NCBI

7 

Nakase K, Tsuji K, Tamaki S, Tanigawa M, Ikeda T, Miyanishi E and Shiku H: Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev. 29:256–259. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Tsujioka T, Kishimoto M, Kondo T, Matsuoka A, Tasaka T, Sugihara T, Wada H and Tohyama K: The impact of serum soluble interleukin-2 receptor levels on the diagnosis of malignant lymphoma. Kawasaki Med J. 37:19–27. 2011.

9 

Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y and Tomonaga M: Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 73:2753–2758. 1994. View Article : Google Scholar : PubMed/NCBI

11 

Murakami S, Satomi A, Ishida K, Murai H, Matsuki M and Hashimoto T: Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer. Cancer. 74:2745–2748. 1994. View Article : Google Scholar : PubMed/NCBI

12 

Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, et al: Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: In combination with the International Prognostic Index. J Cancer Res Clin Oncol. 131:73–79. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Nakashima MO, Roy DB, Nagamine M, Roullet MR, Gabriel CA, Sood SL and Bagg A: Intravascular large B-cell lymphoma: A mimicker of many maladies and a difficult and often delayed diagnosis. J Clin Oncol. 29:e138–e140. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Tabata C and Tabata R: Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome. Ann Hematol. 91:63–71. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Hayden A, Lin M, Park S, Pudek M, Schneider M, Jordan MB, Mattman A and Chen LYC: Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv. 1:2529–2534. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M, Mattman A, Schneider M and Chen LYC: Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: A systematic scoping review. Ann Hematol. 96:1241–1251. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2019
Volume 11 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Murakami, J., Arita, K., Wada, A., Mihara, H., Origasa, H., Kigawa, M. ... Sato, T. (2019). Serum soluble interleukin‑2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. Molecular and Clinical Oncology, 11, 474-482. https://doi.org/10.3892/mco.2019.1922
MLA
Murakami, J., Arita, K., Wada, A., Mihara, H., Origasa, H., Kigawa, M., Yasuda, I., Sato, T."Serum soluble interleukin‑2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions". Molecular and Clinical Oncology 11.5 (2019): 474-482.
Chicago
Murakami, J., Arita, K., Wada, A., Mihara, H., Origasa, H., Kigawa, M., Yasuda, I., Sato, T."Serum soluble interleukin‑2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions". Molecular and Clinical Oncology 11, no. 5 (2019): 474-482. https://doi.org/10.3892/mco.2019.1922